Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapiesSiu Chiu Chan, Scott M. Dehm|Nucleic Acids Research|2015Cited by 151
Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer CellsScott M. Dehm, Donald J. Tindall|Journal of Biological Chemistry|2006Cited by 113
A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate CancerShee Kwan Phung, Martin Felices, Nicholas A. Zorko et al.|Cancer Immunology Research|2024Cited by 9
Evolution of <i>AR</i> and Non- <i>AR</i> Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 TrialJosé C. Valentín López, Scott M. Dehm|Clinical Cancer Research|2026Cited by 1
Supplementary Materials and Methods from Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate CancerJamie L. Van Etten, Scott M. Dehm|Unknown|2023Cited by 0